APOE and dementia: Based on these limitations, we propose using plasma pTau217 as an endophenotype of AD41, 42 within All of Us to better characterize AD prevalence, assess the differential risk of APOE4 allelic dose, and clarify the proportions of AD versus non‐AD dementias in each group.